Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs

Anemia in CKD is associated with increased risk of CKD progression, poor CV outcomes, decreased health-related quality of life, and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Share

Program Content

Activities

  • Lowering the Burden of Anemia in CKD
    Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2022

    Expires: December 19, 2023

Faculty

cover img faculity

Christine M. Chmielewski, MS, CRNP, ANP-BC, CNN-NP

Nephrology Nurse Practitioner 
Department of Nephrology
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

cover img faculity

Matthew Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, MD

cover img faculity

Jay Wish, MD

Professor of Clinical Medicine
Indiana University School of Medicine
Chief Medical Officer for Out-Patient Dialysis
Indiana University Health
Indianapolis, IN

Provided by

ProCE Banner
ProCE Banner

Jointly provided by USFH and Rockpointe.

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline